Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.
Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The authors have previously provided a comprehensive review of SGAs for the treatment of MDD in 2013. Since then, numerous additional clinical trials have been conducted to investigate diverse issues regarding the utility of SGAs in MDD. Moreover, a new SGA, brexpiprazole, was recently approved by the Food and Drug Administration in July 2015 for the treatment of MDD as an augmentation agent to antidepressants. Thus, the aim of this study was to provide a concise update of all the available SGAs for the treatment of MDD, in particular on the additional clinical trials which have been published since 2013.
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; International Health Care Center, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Sheng-Min
SM
Wang
Department of Psychiatry, College of Medicine, Korea University, Korea.
Changsu
C
Han
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
Soo-Jung
SJ
Lee
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.
Tae-Youn
TY
Jun
Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.
Ashwin A
AA
Patkar
Global Medical Education, New York, NY, USA.
Prakash S
PS
Masand
Department of Psychiatry, The Catholic University of Korea College of Medicine, Seoul, Korea.; Department of Psychiatry and Behavioural Sciences, Duke University Medical Center, Durham, NC, USA.
Chi-Un
CU
Pae
Antidepressive Agents; Antipsychotic Agents; Clinical Trial; Depressive Disorder; Depressive Disorder, Treatment-Resistant
Expert Opin Investig Drugs. 2015 Apr;24(4):445-53
25529224
Am J Psychiatry. 2015 Dec;172(12):1251-8
26085041
Int Clin Psychopharmacol. 2001 Nov;16(6):317-24
11712619
J Clin Psychiatry. 2009 Apr;70(4):526-39
19358790
J Psychiatr Res. 2009 Jan;43(3):205-14
18586273
Int Clin Psychopharmacol. 2008 Sep;23(5):269-75
18703936
Int Clin Psychopharmacol. 2012 Jan;27(1):27-39
22027845
Psychiatry Res. 2002 Oct 10;112(2):145-52
12429360
Arch Gen Psychiatry. 2009 Aug;66(8):838-47
19652123
J Clin Psychiatry. 2005 Oct;66(10 ):1289-97
16259543
Psychosomatics. 2009 Jan-Feb;50(1):78-86
19213976
Gen Hosp Psychiatry. 2009 Sep-Oct;31(5):478-83
19703642
Psychiatry Investig. 2015 Oct;12(4):434-42
26508953
J Psychiatr Res. 2015 Mar;62:56-61
25659187
Psychiatr Danub. 2013 Sep;25(3):214-20
24048387
CNS Drugs. 2009 Dec;23(12):1023-37
19958040
J Clin Psychiatry. 2007 Feb;68(2):224-36
17335320
J Clin Psychiatry. 2008 Aug;69(8):1228-336
18681749
Arthritis Rheumatol. 2014 Feb;66(2):451-61
24504819
BMC Psychiatry. 2012 Sep 27;12:160
23017200
Psychiatry Investig. 2016 Jan;13(1):50-7
26766946
J Affect Disord. 2014 Jun;162:20-5
24766999
Psychiatry Investig. 2015 Oct;12(4):421-4
26508951
Depress Anxiety. 2006;23 (6):364-72
16710853
Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32
20175941
J Psychiatr Res. 2015 Jul-Aug;66-67:84-94
26013203
J Clin Psychopharmacol. 2004 Aug;24(4):365-73
15232326
J Clin Psychiatry. 2009 Apr;70(4):540-9
19358791
CNS Spectr. 2009 Apr;14(4):197-206
19407731
Am J Psychiatry. 2006 Nov;163(11):1905-17
17074942
J Clin Psychiatry. 2007 Jun;68(6):843-53
17592907
J Affect Disord. 2002 Aug;70(3):313-7
12128243
Am J Psychiatry. 2016 Apr 1;173(4):400-7
26552942
Neuropsychobiology. 1999;39(1):25-32
9892856
J Clin Psychiatry. 2012 Dec;73(12):1541-7
23290327
Psychiatry Clin Neurosci. 2015 Jan;69(1):34-42
24965202
Lancet. 2015 Dec 12;386(10011):2404-12
26423182
Ann Gen Hosp Psychiatry. 2004 Feb 18;3(1):4
14975068
Chonnam Med J. 2015 Aug;51(2):66-80
26306301
J Psychopharmacol. 2015 May;29(5):565-74
25257148
J Affect Disord. 2011 Jan;128(1-2):83-94
20691481
J Clin Psychiatry. 1999 Apr;60(4):256-9
10221288
J Psychiatr Res. 2014 Feb;49:75-82
24268719
Acta Psychiatr Scand. 2010 Mar;121(3):190-200
19694628
Expert Rev Neurother. 2013 Jul;13(7):851-70
23898855
J Clin Psychiatry. 2015 Sep;76(9):1224-31
26301701
J Clin Psychiatry. 2015 Apr;76(4):e531-3
25919851
Acta Psiquiatr Psicol Am Lat. 1994 Mar;40(1):41-9
8053353
Ann Intern Med. 2007 Nov 6;147(9):593-602
17975181
CNS Spectr. 2009 Jun;14(6):299-313
19668121
J Psychopharmacol. 1999;13(3):248-54
10512080
PLoS Med. 2013;10(3):e1001403
23554581
Am J Geriatr Psychiatry. 2008 Jan;16(1):21-30
17928573
Eur Neuropsychopharmacol. 2006 May;16(4):281-7
16316746
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1165-73
20307622
Neuropsychiatr Dis Treat. 2014 Jan 30;10:201-16
24511235
Int Clin Psychopharmacol. 2002 Jan;17(1):27-32
11800503
Int Clin Psychopharmacol. 2014 Nov;29(6):332-8
24815673
Braz J Med Biol Res. 2014 Jul;47(7):605-16
24919175
Psychiatry Investig. 2015 Apr;12(2):249-59
25866527
J Clin Psychiatry. 2007 Jun;68(6):826-31
17592905
J Pharmacol Exp Ther. 2014 Sep;350(3):605-14
24947464
Psychiatry Investig. 2016 Jan;13(1):157-60
26766959
J Clin Psychopharmacol. 2011 Apr;31(2):245-6
21364337
Int J Neuropsychopharmacol. 2015 May 25;18(11):pyv060
26012350
Am J Psychiatry. 2009 Sep;166(9):980-91
19687129
J Clin Psychopharmacol. 2008 Apr;28(2):156-65
18344725
Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206
23320989
Neuropsychopharmacology. 2006 Nov;31(11):2505-13
16760927
Int J Clin Pract. 2014 Nov;68(11):1301-8
25196314
Am J Psychiatry. 2001 Jan;158(1):131-4
11136647
J Affect Disord. 2013 Dec;151(3):899-905
24074484
J Affect Disord. 2013 Jul;149(1-3):189-95
23639212
Psychiatry Investig. 2015 Jul;12(3):388-96
26207134
Int J Neuropsychopharmacol. 2015 Mar 13;18(8):null
25770098
Depress Anxiety. 2007;24(7):487-94
17177199
J Clin Psychiatry. 2015 Sep;76(9):1232-40
26301771
J Clin Psychiatry. 2015 Apr;76(4):e487-98
25919841
J Affect Disord. 1997 Apr;43(2):95-103
9165379
Drugs. 2015 Nov;75(17):2035-43
26510944
Expert Opin Investig Drugs. 2009 Jun;18(6):767-88
19426122
Psychiatry Investig. 2015 Jul;12(3):417-9
26207140
J Affect Disord. 1998 Feb;48(1):47-56
9495601
Depress Anxiety. 2010 Oct;27(10):964-76
20734365
CNS Spectr. 2014 Dec;19(6):528-34
24642260
Neuropsychopharmacology. 2014 Oct;39(11):2549-59
24801768
BMC Psychiatry. 2008 Aug 28;8:73
18752690